Takeda
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).
Takeda: 408 sponsored US clinical trials, 49 recruiting.
Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.
Top-decile sponsor footprint
Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
408 total, page 4 of 9
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
NCT03814005
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants
NCT03933488
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
NCT03771963
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
NCT03827655
A Study of TAK-951 in Healthy Adults
NCT05567393
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
NCT03801148
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
NCT03746015
Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
NCT03738475
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
NCT03648372
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
NCT03694275
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
NCT03650452
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT03196427
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
NCT03546894
A Study of Soticlestat in Adults and Children With Rare Epilepsies
NCT03635073
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
NCT03522506
Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
NCT03409796
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
NCT03439293
A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
NCT03961308
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
NCT03342898
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
NCT03961295
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
NCT03948581
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
NCT03423173
A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
NCT03949621
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
NCT03486990
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
NCT03281577
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
NCT02559713
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954
rVWF IN PROPHYLAXIS
NCT02973087
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
NCT03343626
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT03138655
Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
NCT03166215
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants
NCT03228433
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants
NCT03173170
Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
NCT03131895
Triple Combination Therapy in High Risk Crohn's Disease (CD)
NCT02764762
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
NCT03029143
A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants
NCT03083639
Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults
NCT03039790
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
NCT02972632
Ixazomib Rollover Study
NCT02924272
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
NCT02932904
TAK-071 Scopolamine-Induced Cognitive Impairment Study
NCT02918266
Phase 3 Alogliptin Pediatric Study
NCT02856113
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
NCT02790138
A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants
NCT02906813
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
NCT02630966
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
NCT02761187
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants
NCT02817516
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
NCT02728895
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 90 |
| Phase 3 | 148 |
| Phase 4 | 26 |
What is open in the Takeda pipeline
49 recruiting of 408 indexed (12% open); 284 completed (70%).
Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).
Top condition: Healthy Volunteers (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Takeda: open-pipeline peers nationwide
Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 408 trials (± recruiting share)
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Arcus Biosciences · 12% recruiting · 25 trials
- Ardelyx · 12% recruiting · 25 trials
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- East Carolina University · 12% recruiting · 58 trials
Related
What to do with this Takeda page
408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.
- 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.